Proximal PSA Predicts Prostate Cancer Metastasis Risk
PSA levels of 10 ng/mL or higher in men who have biochemically recurrent PCa after radical prostatectomy and a PSADT less than 12 months are at imminent risk for metastatic disease.
PSA levels of 10 ng/mL or higher in men who have biochemically recurrent PCa after radical prostatectomy and a PSADT less than 12 months are at imminent risk for metastatic disease.
A detectable PSA nadir combined with shorter time to nadir after prostate cancer surgery is associated with a higher risk of biochemical recurrence.
Over 15 years of follow-up, considerable proportion of men undergo prostate-specific antigen testing
Men with PSA values of 2.5 ng/mL or less and Gleason 8 to 10 prostate tumors are at higher risk of death than other high-risk PCa patients.
The new test, IsoPSA, measures all PSA isoforms in serum and more accurately discriminates high-grade cancer from benign disease.
Spike in PSA level after starting abiraterone does not affect progression-free or overall survival, study finds.
Also increased risk of progression to metastatic disease compared with the general population.
The US Preventive Services Task Force now suggests decisions about PSA testing should be made on an individual basis for men aged 55 to 69.
Pathologic Gleason scores, positive surgical margin rates, and PSA doubling times differentiate earlier from later biochemical recurrence after radical surgery.
In 2014, 33.9% of men reported that their health care providers failed to communicate the benefits and risks of PSA-based screening, an increase from 2012.